Following a May phase II readout and a recent presentation of Tourmaline Bio Inc.’s long-acting anti-IL-6 IgG2 monoclonal ...

Elutia Inc. agreed to sell its Elupro and Cangaroo bioenvelopes for implantable medical devices to Boston Scientific Corp. for $88 million in cash. Elutia will use the funds to further development of ...

Neurosciences specialist NRG Therapeutics Ltd. is poised to put its new class of small-molecule regulators of the ...

Braveheart Bio Inc. is paying $65 million up front to license Jiangsu Hengrui Pharmaceuticals Co. Ltd.’s oral hypertrophic ...

Companies developing AI-based health care solutions need to ensure they have quality data, a solution that can easily ...

It offers bladder cancer patients a new option prior to a radical cystectomy, or bladder removal surgery, by delivering cancer medication into the bladder, where it is released for three weeks per ...

Small fiber neuropathy (SFN) is a chronic and debilitating condition caused by damage to peripheral sensory nerves, which are ...

The U.S. Office of Inspector General posted an analysis of Medicare spending on skin substitutes, remarking that the data ...

Daiichi Sankyo Co. Ltd. and Merck & Co. Inc.’s antibody-drug conjugate (ADC) ifinatamab deruxtecan produced a confirmed 48.2% ...

For treating bipolar disorder, investigators have explored single strategies targeting dopamine receptors or the glycogen ...

Robust efficacy, competitive tolerability and ease of administration. Those are the qualities for a potential blockbuster ...

The U.S. Federal Trade Commission has opened a docket for comment on noncompete employment contracts, a move which suggests that the agency may revert to evaluating these practices on a case-by-case ...